Navigation Links
VIB-K.U. Leuven scientists clear the way to alternative anti-angiogenic cancer therapy
Date:1/7/2011

Leuven Scientists attached to VIB and K.U.Leuven have succeeded in decoding a potential new anti-cancer mechanism. The researchers discovered that normalizing abnormal tumor blood vessels through HRG (histidine-rich glycoprotein) prevents metastasis of tumor cells and enhances chemotherapy efficiency. In tumors, vessels formation is disturbed, leading to inefficient delivery of chemotherapeutic drugs and allowing cancer cells to escape to other parts of the body (metastasis). The normalization of tumor blood vessel formation through HRG works by repressing the production of the Placental Growth Factor PlGF. Anti-PlGF therapy is now being tested as a new agent against cancer by ThromboGenics in collaboration with Roche. The recently discovered mechanism offers alternative possibilities for cancer treatment.

Cancer and the formation of blood vessels (angiogenesis)

Every growing tissue is supplied with oxygen and nutrients through our blood vessels. However, tumors grow much faster than normal tissue and have a higher need for nutrients. Consequently, tumor cells start generating growth factors to stimulate the growth of new blood vessels. However, the resulting blood vessels are of abnormal shape, causing poor blood flow and little oxygen supply to the cancer cells. The oxygen shortage encourages cancer metastasis and eventually leads to a malignant cancer. Furthermore, the abnormal shape of the blood vessels hampers the supply and efficiency of anti-cancer drugs.

Conventional anti-angiogenic therapy

Conventional anti-angiogenic cancer therapy in which a growth factor is eliminated may aggravate tumor metastasis, becase. Because of this, there has in recent years been a greater focus on anti-angiogenic therapies which normalize the blood vessels supplying the tumor. This would reduce the oxygen shortage, with the result that the cancer cells will tend to travel less to other parts of the body and anti-cancer drugs can be delivered more efficiently.

Histidine-rich glycoprotein (HRG)

Charlotte Rolny, Max Mazzone and their colleagues from the VIB Vesalius Research Center, K.U.Leuven, have under the direction of Peter Carmeliet and in collaboration with VIB researchers from the Vrije Universiteit Brussel and colleagues from Sweden studied the mechanism behind the known anti-cancer activity of the protein HRG. The results of their experiments show that HRG, a protein distributed in the tumor stroma, displays anti-cancer activity by combating tumor progression and spread and stimulating normalization of tumor blood vessels. The underlying basis of this action is the capacity of HRG to suppress the angiogenic factor PlGF.

Towards an alternative cancer therapy

Revealing the mechanism behind the anti-cancer activity of HRG opens up new horizons for cancer treatment. The larger a tumor becomes, the higher its oxygen requirement. However, the tumor vessels that are formed are abnormal in shape, leading to poor blood and oxygen flow. This oxygen shortage stimulates cancer cell metastasis. Stimulating HRG in the tumor stroma counters tumor progression and spread while at the same time being conducive to normalization of tumor blood vessels which enhances the efficacy of chemotherapy. Moreover, these data also support eliminating PlGF for the treatment of cancer.


'/>"/>

Contact: Joris Gansemans
joris.gansemans@vib.be
32-924-46611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related medicine news :

1. Damon Runyon Cancer Research Foundation awards prestigious fellowships to 12 top young scientists
2. Scientists Aim for Test That Spots Single Cancer Cell in Blood Sample
3. Scientists Aim for Test That Could Spot Single Cancer Cell in Blood
4. Scientists Spot DNA Linked With Dangerous Heart Rhythms
5. Ion channel responsible for pain identified by UB neuroscientists
6. Scientists decode secrets of a very common virus that can cause cancer
7. Scientists Spot Genetic Areas Key to Embryonic Development
8. UNC scientists discover potential strategy to improve cancer vaccines
9. Scientists Raise Fat-Burning Levels in Mice
10. Scripps Research scientists awarded $2.35 million to study new obesity treatment
11. NIH scientists identify mechanism responsible for spreading biofilm infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... FL (PRWEB) , ... April 29, 2016 , ... ... will feature Grassland Dairy Products, Inc. in an upcoming episode, airing third quarter ... a century of churning cream into butter, Grassland Dairy Products, located in Greenwood, ...
(Date:4/29/2016)... ... April 29, 2016 , ... Nike Softball Camp at the College of Brockport ... 27th for girls aged 10-18. All facets of the game will be covered; hitting, ... Whited Complex, one of the finest softball facilities in the region. The outstanding professional ...
(Date:4/29/2016)... ... 29, 2016 , ... Coalition Duchenne, a Newport Beach, California ... Duchenne research, participated in the April 25 U.S. Food and Drug Administration advisory ... The meeting at the Marriott Conference Center in Hyattsville, Maryland was attended by ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... Pro3rd ... X. Utilize Pixel Film Studios’ lower thirds to introduce people, characters, and locations without ... that include boxes, lines, accents, textures and many more design components. Simply select a ...
(Date:4/29/2016)... ... 29, 2016 , ... Orthodontics Limited, one of the nation’s ... Dr. Middleberg, were asked by Invisalign to present an “Ask the ... titled “Advancing the Biomechanics of Invisalign Clear Aligners,” Dr. Gemmi and Dr. Middleberg ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 ... , George Phillips und ... Unternehmens    ArisGlobal®, ein führender ... Sciences, gab heute bekannt, dass neue Führungskräfte ... Unternehmens gestoßen sind, die vielfältige Erfahrungen mitbringen. ...
(Date:4/28/2016)... 2016 Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, announced ... 2016 conference, presented by Joseph Gunnar & Co. ... New York . Nadav Kidron , CEO of ... Presentation Details:   PIONEERS 2016, presented ...
(Date:4/27/2016)... Mass., April 27, 2016  Hologic, Inc. (Nasdaq: ... financial results for the fiscal second quarter ended ... (EPS) of $0.24 increased 41.2%, and non-GAAP diluted ... million increased 5.8% on a reported basis, and ... "We posted another good quarter, highlighted by ...
Breaking Medicine Technology: